[{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KTX-0200","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Kintai Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kintai Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"NM-136","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NM-136","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sunstone Life Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"RES-010","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Resalis Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Sunstone Life Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Resalis Therapeutics \/ Sunstone Life Science Ventures"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TT-02332","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TransThera Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"DA-1726","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeuroBo Pharmaceuticals \/ Not Applicable"}]

Find FDA Investigational New Drug (IND) Submissions for Nutrition and Weight Loss

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : BLX 0871 is an AMPK activator, which is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.

                          Brand Name : BLX 0871

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 29, 2024

                          Lead Product(s) : BLX 0871

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010 for the treatment of obesity.

                          Brand Name : RES-010

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : RES-010

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.

                          Brand Name : AT-7687

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          October 09, 2024

                          Lead Product(s) : AT-7687

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : ARO-INHBE, a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.

                          Brand Name : ARO-INHBE

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 23, 2024

                          Lead Product(s) : ARO-INHBE

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TT-02332 is a novel, highly potent and CNS-penetrating NLRP3 inhibitor. It is being evaluated for the treatment of obesity, inflammatory bowel disease & dermatitis.

                          Brand Name : TT-02332

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 26, 2024

                          Lead Product(s) : TT-02332

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist, which is currently being evaluated for the treatment of obesity.

                          Brand Name : DA-1726

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          February 01, 2024

                          Lead Product(s) : DA-1726

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : VERU-024 (enobosarm) is a novel selective AR modulator which is beig evaluated in preclinical studies to prevent muscle loss while augmenting fat loss in combination with GLP-1 drugs for weight loss.

                          Brand Name : VERU-024

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 08, 2024

                          Lead Product(s) : Enobosarm,Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program RES-010, a non-coding RNA-based compound, in obesity.

                          Brand Name : RES-010

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 04, 2024

                          Lead Product(s) : RES-010

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Sunstone Life Science Ventures

                          Deal Size : $11.0 million

                          Deal Type : Series A Financing

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Veru intends to use the proceeds to fund its clinical stage drug development, including a Phase 2b trial to evaluate VERU-024 (enobosarm), an oral selective androgen receptor modulator, for the treatment to augment fat loss and to prevent muscle loss in ...

                          Brand Name : VERU-024

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 14, 2023

                          Lead Product(s) : Enobosarm,Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Raymond James & Associates

                          Deal Size : $33.0 million

                          Deal Type : Public Offering

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Veru intends to use the proceeds to fund its clinical stage drug development, including a Phase 2b trial to evaluate VERU-024 (enobosarm), an oral selective androgen receptor modulator, for the treatment to augment fat loss and to prevent muscle loss in ...

                          Brand Name : VERU-024

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : Enobosarm,Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Raymond James & Associates

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank